Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

D. Lee (), A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell and Y. Meng
Additional contact information
D. Lee: BresMed Health Solutions
A. Amadi: Bristol-Myers Squibb Pharmaceuticals
J. Sabater: Bristol-Myers Squibb
J. Ellis: Bristol-Myers Squibb Pharmaceuticals
H. Johnson: Helen Johnson Consulting Ltd
S. Kotapati: Bristol-Myers Squibb
S. McNamara: University of Sheffield
A. Walker: Salus Alba
M. Cooper: BresMed Health Solutions
K. Patterson: BresMed Health Solutions
N. Roskell: BresMed Health Solutions
Y. Meng: BresMed Health Solutions

PharmacoEconomics - Open, 2019, vol. 3, issue 1, No 12, 127-127

Abstract: The second Key Point for Decision Makers, which reads:

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-018-0096-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:1:d:10.1007_s41669-018-0096-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-018-0096-x

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().